Human evidence,
from target to IND.

NEURXSTEM applies the NNOP™ platform to disease-specific programs across Alzheimer's, Parkinson's, aging and senescence, migraine, autism, opioid and substance use disorder, neuroinflammation, and glymphatic function. Direct concordance with human clinical tissue gives programs evidence aligned with FDA human-data expectations under the FDA Modernization Act, rather than the animal-model approximations that have driven decades of failed CNS translation. Animal models do not predict human brain disease — and that gap has driven decades of failed CNS translation. NEURXSTEM replaces approximation with human biology: patented whole-brain organoids that generate reproducible, regulator-grade molecular data.